Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

06/10/2026, 1:00 PM • GlobeNewswire

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon Pharmaceuticals announced positive Phase 3 X-TOLE2 study results for azetukalner, a KV7 potassium channel opener for focal onset seizures, showing 53.2% reduction in monthly seizure frequency at 25mg versus 10.4% for placebo. Long-term data from the 48-month X-TOLE open-label extension study demonstrated nearly 40% of participants achieved at least 12 months of seizure freedom. The company plans to submit a New Drug Application to the FDA in Q3 2026.

04/19/2026, 6:00 PM • GlobeNewswire

Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know

Xenon Pharmaceuticals' chief medical officer sold 1,410 shares worth $78,000 on March 13, 2026, representing a routine RSU vesting and sell-to-cover transaction. The stock has surged 55% following positive Phase 3 trial results for its lead candidate azetukalner and a $750 million capital raise. Despite significant losses ($345.9M in 2025), the well-capitalized biotech remains a binary bet on its neurological drug pipeline.

03/27/2026, 7:03 PM • The Motley Fool

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Xenon Pharmaceuticals priced an upsized public offering of 10.5 million common shares at $57.00 per share and pre-funded warrants, expected to raise approximately $650 million gross proceeds. The offering is expected to close on March 12, 2026, with J.P. Morgan, Jefferies, and other major underwriters managing the deal.

03/10/2026, 10:39 PM • GlobeNewswire

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million

Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.

02/23/2026, 10:18 AM • The Motley Fool

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals granted 39,250 share options to five new non-officer employees, with options vesting over four years and an exercise price of $44.61 per share.

12/04/2025, 5:20 PM • GlobeNewswire

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals granted 24,200 share options to six new non-officer employees, with an exercise price of $30.54 per share, vesting over four years.

08/01/2025, 4:55 PM • GlobeNewswire